Expanded access to upadacitinib
Treatments studied
Part of Bones, joints & muscles, Brain & nervous system, Digestive system, Genetic & congenital, Heart & circulation, Immune system & allergy, Infections, Skin clinical trials.
This program provides early access to upadacitinib, a medication that may help treat your condition when other options are not suitable. It is designed for patients who cannot join a clinical trial but have no other treatment choices.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have no other suitable treatment options available.
- You do not qualify for any ongoing clinical trials.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a medication called upadacitinib for people with inflammatory bowel disease (ulcerative colitis or Crohn's). The goal is to see how well it works and if it's safe.
This study tests an oral tablet called upadacitinib for people with severe alopecia areata who have lost at least half of their scalp hair. It aims to see if the drug can safely help hair regrow.
This study compares the effectiveness of a pill (upadacitinib) with several biologic injections (biologics are medicines that target specific parts of the immune system) in controlling moderate-to-severe atopic dermatitis (eczema). The goal is to see which treatment helps people achieve minimal disease activity, meaning their eczema is under good control.
This study tests how well upadacitinib (a pill taken daily) works for people with active psoriatic arthritis that also affects the spine. It is for those who have not responded well enough to other treatments like NSAIDs or biologics.
This study is looking at how well the drug upadacitinib works and how safe it is for Chinese adults with moderate to severe ulcerative colitis. It is not a treatment trial, but will observe patients who are already taking upadacitinib as decided by their doctor.
This study tests whether a higher dose of upadacitinib (45 mg) can help people with ulcerative colitis whose symptoms come back while on the usual 30 mg maintenance dose. If you've lost response to your current treatment, this re-induction approach may help you get back into remission.
Hear when a new Ulcerative Colitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.